Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Cash from Financing Activities (2016 - 2025)

CytomX Therapeutics' Cash from Financing Activities history spans 12 years, with the latest figure at $16.6 million for Q4 2025.

  • For Q4 2025, Cash from Financing Activities rose 640.02% year-over-year to $16.6 million; the TTM value through Dec 2025 reached $110.4 million, up 1368.31%, while the annual FY2025 figure was $110.4 million, 1368.31% up from the prior year.
  • Cash from Financing Activities reached $16.6 million in Q4 2025 per CTMX's latest filing, up from $253000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $108.7 million in Q1 2021 to a low of $7000.0 in Q1 2022.
  • Average Cash from Financing Activities over 5 years is $16.2 million, with a median of $567000.0 recorded in 2021.
  • Peak YoY movement for Cash from Financing Activities: skyrocketed 4941.03% in 2021, then tumbled 99.99% in 2022.
  • A 5-year view of Cash from Financing Activities shows it stood at $683000.0 in 2021, then tumbled by 72.18% to $190000.0 in 2022, then rose by 28.42% to $244000.0 in 2023, then surged by 821.72% to $2.2 million in 2024, then surged by 640.02% to $16.6 million in 2025.
  • Per Business Quant, the three most recent readings for CTMX's Cash from Financing Activities are $16.6 million (Q4 2025), $253000.0 (Q3 2025), and $93.6 million (Q2 2025).